Athira Pharma to present data from preclinical studies of ATH-1105

Athira Pharma announced that a symposium presentation highlighting data from preclinical studies of ATH-1105 as a potential treatment candidate for amyotrophic lateral sclerosis will be delivered at the upcoming Motor Neurone Disease Association 34th International Symposium on ALS/MND, to be held December 6 – 8, 2023 in Basel, Switzerland. We look forward to the presentation of these data, which highlight the potential of ATH-1105 as a treatment for ALS and add to the growing body of scientific and clinical data that support the potential benefits of our small molecule therapeutic candidates targeting the neurotrophic HGF system as novel treatments for neurodegenerative diseases,” stated Mark Litton, Ph.D., President and Chief Executive Officer of Athira. “These data, which include preclinical data showing prolonged survival and demonstrating consistent improvements in motor function, nerve function, biomarkers and nerve morphology in a transgenic mouse model of ALS, strongly support confidence in our plans to advance this program into human clinical studies in the first half of 2024.”